

## CURRICULUM VITAE

### **Antonia Maria Susanne Müller, MD**

DOB July 9th 1975 in Stuttgart Bad-Cannstatt, Germany



#### Contact Information:

##### Work:

University Hospital Zurich  
Department of Hematology  
Rämistrasse 100  
CH-8091 Zurich, Switzerland  
Phone: ++41 44 255 5371  
Email: [AntoniaMaria.Mueller@usz.ch](mailto:AntoniaMaria.Mueller@usz.ch)

##### Private:

Seestrasse 149, 8704 Herrliberg  
Phone ++41 78 972 3830

---

#### **Current position**

- **Attending** in Hematology / Hematopoietic Cell Transplantation, University Hospital Zurich
- Director of Apheresis and of the Stem Cell Laboratory
- Director Autologous Program

#### **Clinical Training**

08/2014

#### **Board Certification Int. Medicine / Hematology & Oncology**

04/2012-12/2014

**Fellowship** in Hematology  
University Hospital Zurich, Division of Hematology, Switzerland  
Training FAMH (Medical Laboratories of Switzerland)

11/14 – present

05/2002-12/2005

**Residency Internal Medicine** (Hematology/Oncology)  
Department of Hematology/Oncology,  
University Medical Center Freiburg, Germany

01-03/2002

**Subinternship** Neuro-oncology, Memorial Sloan Kettering  
Cancer Center, New York, NY

1996-2001

**Electives** at  
Robert-Bosch-Hospital, Stuttgart, Germany;  
Lainzer Hospital, Vienna, Austria;  
Groote-Schuur Hospital, Cape Town, South Africa;  
University Hospital Freiburg

#### **Experimental and Clinical Research**

01/2013 to present

**Group leader:** within the Experimental Hematology laboratory:

- Immune-mediated changes of the bone marrow following allogeneic stem cell transplantation. Graft-versus-Host & Graft-versus-Leukemia: Effects
- Reconstitution of T-cell immunity against cytomegalovirus following allogeneic hematopoietic cell transplantation
- Characterization and long-term outcome after allogeneic hematopoietic cell transplantation in patients with high-risk acute myelogenous leukemia at the University Hospital Zurich

2010-2012

**Research Associate** in J Shizuru's laboratory, Division of Blood & Marrow Transplantation, Stanford University, Stanford, CA, US  
- Focus: immune reconstitution and GVHD post allogeneic HCT

- 2006-2009 **Postdoctoral Research Fellow** in J Shizuru's laboratory  
Div. of Blood & Marrow Transplantation, Stanford Univ., CA, US
- 1998-2002 **MD thesis:** Gene expression of annexin II and ribosomal protein LP23A and cytokine analysis in juvenile myelomonocytic leukemia, Thesis advisor: Charlotte Niemeyer, MD PhD  
University Children's Hospital Freiburg, Freiburg, Germany

### Clinical Trials

- 2016 to present Principal Investigator and Co-PI in several clinical trials related to allogeneic hematopoietic cell transplantation, GVHD, immunomodulation, and high-dose chemotherapy with autologous stem cell rescue
- 2012 to present Co-investigator for HOVON/SAKK trials for the treatment of patients <65 year and >65 years with AML/RAEB-2
- 2003-2005 Co-investigator on several clinical phase II/III trials, mostly related to high-dose chemotherapy and autologous retransfusion
- 04-10/2003 Part-time project coordination: The Clinical Trials Unit at the University Medical Center Freiburg

### Teaching Experience

- 10/2013 until present Group Course, Internal Medicine, University Zurich 01/2013 until present  
Supervision of PhD Student, Cancer Biology Program
- 2009-2011 Supervision of a PhD Student, Stanford University
- 2004 Assistant in the "Clinical Hematology Course" for medical students (University Medical Center, Freiburg i.Br., Germany)

### Education

- 1995-2002 **Candidate for M.D.**  
School of Medicine, Albert-Ludwigs University, Freiburg  
State Board Exams in 1998, 2001, and 2002

### Honors, Awards

- 2006-2007 Postdoctoral Research Fellowship, German Research Foundation (*"Murine models of chronic Graft-vs-Host Disease"*)
- 2013-2016 Project funding by the Swiss Cancer League for *"Improving Graft-versus-tumor Effects by Donor Vaccination with WT1-peptide and Transplantation of Tailored Hematopoietic Grafts"*
- 2014 Cancer League Zurich, Project funding *"Intestinal microbial changes in patients with acute leukemias during chemotherapy"*
- 2014 URPP (University Research Priority Program), Translational Cancer Research: *"Reconstitution of blood & immune function, GVHD-, and GVL-effects – unraveling the complex relationships in the bone marrow after blood stem cell transplantation"*
- 2014 SFK / Stiftung zur Förderung der Knochenmarktransplantation - Candy Heberlein Award; *"Complex Interactions following allogeneic hematopoietic cell transplantation – Immunefunction, pharmacological immunosuppression, GVHD and CMV-reactivation"*
- 2014 Transplantation-Center University Hospital Zurich: Award for best scientific experimental publication in transplantation.

- 2014 Kurt & Senta Hermann Foundation: Project Funding “*Reconstitution of blood formation and immune function, graft-vs-host disease and graft-vs-leukemia effects*”
- 2015 Support from the PROMEDICA Foundation: “Wissenschaftliche Oberarztstelle” for 2 years: start 04/2016 (80% protected research time)
- 2017 Support from the Swiss Transplant Cohort Study (STCS); project: *Reconstitution of T cell immunity against cytomegalovirus (CMV) following allogeneic hematopoietic cell transplantation (HCT)*

## PUBLICATIONS

### Original papers

1. Wilk CM, Weber I, Seidl K, Rachmühl C, Holzmann-Bürgel A, Müller AM, Kuster SP, Schanz U, Zinkernagel AS (2017) Impact of oral gut decontamination on *Staphylococcus aureus* colonization in patients undergoing allogeneic hematopoietic stem cell transplantation *International Journal of Antimicrobial Agents*. Accepted for publication at the *International Journal of Antimicrobial Agents*
2. \*Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA (2016) Blood stem cell activity is arrested by T<sub>H</sub>1-mediated injury preventing engraftment following non-myeloablative conditioning. *Journal of Immunology*, 197(10):4151-4162
3. \*\*Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang P, Negrin RS, Shizuru JA (2014) Donor hematopoiesis in mice following total lymphoid irradiation requires host T regulatory cells for durable engraftment. *Blood* 123:2882-2892  
Impact factor: 11.841 (2015), 10.452 (2014)
4. \*Müller AM, Shashidhar S, Küpper N, Kohrt HE, Florek M, Negrin R, Brown J, Shizuru JA (2012) Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity *Proceedings of the National Academy of Sciences (PNAS) USA* 109:5820-5825
5. \*\*Müller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino A, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA (2012) Long-term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. *Biology of Blood and Marrow Transplantation* 18:125-133
6. \*Müller AM, Linderman JA, Florek M, Miklos D, Shizuru JA (2010) Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. *Proceedings of the National Academy of Sciences (PNAS) USA* 107:14721-14726
7. Müller AM, Martens UM, Hofmann S, Bruckner-Tuderman L, Mertelsmann R, Lübbert M (2006) Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. *Annals of Hematology* 85:1-16
8. Müller AM, Ihorst G, Waller CF, Dolken G, Finke J, Engelhardt M (2006) Intensive chemotherapy with autologous peripheral blood stem cell transplantation during a 10-year period in 64 patients with germ cell tumor. *Biology of Blood and Marrow Transplantation* 12:355-365
9. Müller AM, Geibel A, Neumann H, Kühnemund A, Schmitt-Gräff A, Böhm J, Engelhardt M (2006) Primary (AL) amyloidosis in plasma cell disorders. *The Oncologist* 11:824-830

10. Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S (2015) Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.  
*Clinical Cancer Research* 21:3727-3739
11. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R (2014) Targeting CD137 enhances the efficacy of cetuximab.  
*Journal of Clinical Investigation* 124:2668-2682
12. Filatenkov A, Baker J, Müller AM, Ahn G-O, Kohrt HE, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S (2014) Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion.  
*Radiation Research* 182:163-169
13. Florek M, Sega EI, Leveson-Gower D, Baker J, Müller AM, Meyer E, Negrin RS (2014) Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models.  
*Blood* 124:1832-1842
14. Ali SR, Ranjbarvaziri S, Talkhabi M, Subat A, Volz K, Zhao P, Müller AM, Red-Horse K, Weissman IL, Ardehali R (2014) Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation.  
*Circulation Research* 115:625-635
15. \*\*Kohrt HE, Müller AM, Baker J, Goldstein MJ, Newell E, Dutt S, Czerwinski D, Lowsky R, Strober S (2011) Donor immunization with WT1 peptide augments anti-leukemic activity after MHC-matched bone marrow transplantation.  
*Blood* 118:5319-5329
16. Kohrt HE, Houot R, Goldstein M, Weiskopf K, Alizadeh AA, Brody J, Müller AM, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder T, Levy R (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.  
*Blood* 117:2423-2432
17. Udi J, Wider D, Kleber M, Ihorst G, Müller AM, Wäsch R, Engelhardt M (2011) Endothelial progenitor cells, hemangioblasts and VEGFR2<sup>+</sup>-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments.  
*Leukemia Research* 35:1265-1268
18. Filatenkov A, Müller AM, Tseng WW, Dejbakhsh-Jones S, Winer D, Luong R, Shizuru JA, Engleman EG, Strober S (2009) Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation.  
*Journal of Immunology* 183:7196-7203

#### **Brief Reports / Letters to the Editor / Case presentations**

1. Wehrli M, Oppliger E, Gattiker HH, Manz MG, Müller AMS\*, Goede JS\* (\*marks equal contribution) (2017) Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement  
*The Oncologist* 22(4):480-483
2. Kiesel H, Müller AM, Schmitt-Graeff A, Veelken H (2009) Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations.  
(Bench-to-Bedside Report)

*Cancer Biology & Therapy* 8:319-321

3. Engelhardt M, Müller AM, Maier W, Wäsch R (2005) Severe irreversible bilateral hearing loss after bortezomib (VELCADE(R)) therapy in a multiple myeloma (MM) patient. (Correspondence)  
*Leukemia* 19:869-870
4. Müller AM, Betz MJ, Kromeier J, Ghanem NA, Geibel A, Imdahl A, Frydrychowicz AP (2006) Acute pneumopericardium due to intestino-pericardial fistula.  
(Images in cardiovascular medicine)  
*Circulation* 114:e7-9

### Reviews

1. Müller AM, Duque J, Shizuru JA, Lübbert M (2008) Complementing mutations in core binding factor leukemias: from mouse models to clinical applications.  
*Oncogene* 27:5759-5773
2. Müller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005). Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.  
*Annals of Hematology* 84:1-12
3. Müller AM, Rawluk J, Thierry V, Brink I, Engelhardt M (2005) Innovative antibody-therapies for malignant lymphomas.  
*Deutsche Medizinische Wochenschrift* 130:2783-2788
4. Hofmann SC, Technau K, Müller AM, Lübbert M, Bruckner-Tuderman L (2007). Bullous pemphigoid associated with hypereosinophilic syndrome: Simultaneous response to imatinib.  
*Journal of the American Academy of Dermatology* 56:S68-72

### Book Chapters

1. Müller AM, Florek M (2014) 5-Azacytidine/ Azacitidine. In: Recent Results in Cancer Research: Small Molecules in Oncology. Martens, U.M. (eds), pp. 299-324, Springer Berlin Heidelberg.
2. Müller A, Zürcher G. (2008) Nutrition in Cancer Patients. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 225-234, Springer. Heidelberg Berlin New York
3. Müller A, Scheele J. (2008) Inhibition of Angiogenesis. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 319-321, Springer. Heidelberg Berlin New York
4. Scheele JS, Müller A, Martens U. (2008) Pharmacogenetics and Pharmacogenomics. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 201-203, Springer. Heidelberg Berlin New York
5. Thierry V, Müller A, Engelhardt M, (2008) Growth Factors. In: Concise Manual of Hematology and Oncology (German edition: Das Rote Buch - Hämatologie und internistische Onkologie. 4th edition 2009). Berger D.P., Engelhardt M., Henss H., Mertelsmann R. (eds) pp. 218-224, Springer. Heidelberg Berlin New York

### Other publications

1. Houot R, Pachynski R, Czerwinski DK, Goldstein MJ, Sagiv-Barfi I, Brody J, Müller AM, Marabelle A (2016) Holbrook Kohrt: In Memoriam (1977-2016).  
*Clinical Cancer Research* 22:3695-3696